Kymera Therapeutics

KYMR

Biotech & pharmaceuticals

$112.40vs prev close▲+3.10(+2.84%)

$55.2652W Range$130.05

76% from low

-2.56 (-2.23%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

4 buys

Concentrated buys

1M net buy

+$9.8M

≈ +90K shares

Portfolio Weight

No data

Holding ETFs

—

Not held

Trade Intensity

Minor adjustment

Basis: 0 sells · 4 buys in 1M

Trade Log4-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.09	BUY	ARKG	2,344	$112.40	$263.5K
26.10.08	BUY	ARKG	43,453	$109.30	$4.7M
26.10.07	BUY	ARKG	24,895	$108.35	$2.7M
26.10.06	BUY	ARKG	19,637	$105.98	$2.1M

10.09BUY

2,344

ARKGClose$112.40Est. total$263.5K

10.08BUY

43,453

ARKGClose$109.30Est. total$4.7M

10.07BUY

24,895

ARKGClose$108.35Est. total$2.7M

10.06BUY

19,637

ARKGClose$105.98Est. total$2.1M

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$139.35

vs Current ▲ +24.0% upside

Current$112.40

Low ~ High$111.00 ~ $180.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Raymond James

Outperform

$140.00

+24.56%

—

Upgrade

2026-10-09

Citigroup

Buy

$150.00

+33.45%

—

Maintain

2026-10-05

Stifel

Buy

$152.00

+35.23%

—

Maintain

2026-09-22

B of A Securities

Buy

$144.00

+28.11%

—

Maintain

2026-09-14

Wolfe Research

Outperform

N/A

—

Upgrade

2026-09-10

1 / 4

Avg Target

$139.35

vs Current ▲ +24.0% upside

Strong Buy

24 analysts

Strong Buy 5Buy 17Hold 2

Low $111.00

Current $112.40

High $180.00

Firm	Position	Target	Upside	Close	Action	Date
Raymond James	Outperform	$140.00	+24.56%	—	Upgrade	26.10.09
Citigroup	Buy	$150.00	+33.45%	—	Maintain	26.10.05
Stifel	Buy	$152.00	+35.23%	—	Maintain	26.09.22
B of A Securities	Buy	$144.00	+28.11%	—	Maintain	26.09.14
Wolfe Research	Outperform	N/A	N/A	—	Upgrade	26.09.10

1 / 4

Price Information

Previous Close$109.30

Open$109.54

Day Range$107.46 - $115.81

52-Week Range$55.26 - $130.05

1-Year Change87.68%

Trading Volume

Volume1,305,180

Avg Volume (3mo)715,625

Valuation

Market Cap9.2B

Book Value$18.23

Shares Outstanding82,257,588

Financials

Revenue (TTM)105.0M

Net Income-299,600,992

EPS$-3.25

EBITDA-339,891,008

Profitability

P/E Ratio-

P/B Ratio6.17

Return on Equity (ROE)-24.15%

Return on Assets (ROA)-15.59%

Profit Margin-285.33%

EV/EBITDA-25.70

Beta1.98

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)42.50

Company Overview

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drugs that degrade disease-causing proteins using the body's natural protein degradation system. Its lead programs include oral degraders for atopic dermatitis, asthma, and autoimmune diseases, as well as oncology targets. The company has a strategic alliance with Sanofi and is headquartered in Watertown, Massachusetts.

P/B

6.17

High valuation

ROE

-24.1%

Persistent loss

Beta

1.98

High volatility

RSI(14)

42.5

Neutral zone

AI-generated summary. Not investment advice.

Kymera Therapeutics

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks